Appropriate use of non-steroidal anti-inflammatory drugs in rheumatology: Guidelines from the Spanish Society of Rheumatology and the Mexican College of Rheumatology;Uso apropiado de los antiinflamatorios no esteroideos en reumatología: Documento de consenso de la Sociedad Española de Reumatología y el Colegio Mexicano de Reumatología

Reumatologia Clinica

Volumn 5, Issue 1, 2009, Pages 23-27

  Segura, Gerardo Bori ^a   Cruz, Blanca Hernández ^b   Gobbo, Milena ^c   Arbeloa, Ángel Lanas ^d   Páramo, Mario Salazar ^e   Estrada, Leobardo Terán ^f   González, José Federico Díaz ^g   Morales, Rolando Espinosa ^h   Villegas, Federico Galván ⁱ   Rodríguez, Luis Alberto García ^j   Álvaro, José María Gracia ^k   Armengol, Hilario Ávila ^l   Carmona, Loreto ^c   Redondo, Javier Rivera ^m   Ríos, Lucio Ventura ⁿ  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^c UNIDAD DE INVESTIGACIÓN   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^e UNIVERSITY OF GUADALAJARA   (Mexico)

^f Departamento de Medicina Interna   (Mexico)

^g HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^h INSTITUTO NACIONAL DE REHABILITACIÓN   (Mexico)

ⁱ HGR No 1 IMSS   (Mexico)

^j Centro Español de Investigación Farmacoepidemiológica ^*  (Spain)

^k HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^l HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^m Instituto Provincial de Rehabilitacion   (Spain)

ⁿ HOSPITAL CENTRAL SUR DE ALTA ESPECIALIDAD   (Mexico)

more..

Author keywords

Anti inflammatory agents; Delphi technique; Guideline; Review

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR RISK; DELPHI STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; LIVER TOXICITY; MEDICAL SOCIETY; METHODOLOGY; MEXICO; NEPHROTOXICITY; PHYSICIAN; PRACTICE GUIDELINE; RHEUMATIC DISEASE; RHEUMATOLOGY; SPAIN;

EID: 67649619295     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/S1699-258X(09)70200-1     Document Type: Article

References (43)

1. Fosbol EL, Gislason GH, Jacobsen S, Abildstrom SZ, Hansen ML, Schramm TK, et al. The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. Pharmacoepidemiol Drug Saf. 2008. [revista on-line; citado 1 Jul 2008]. Disponible en: http://www3.interscience.wiley.com/journal/5669/home
2. Ballina FJ, Carmona L, Laffon A, Grupo de Estudio EPISER. Impacto del consumo de AINE en la población general española: Resultados del estudio EPISER. Rev Esp Reumatol. 2002;29:337-342
3. Grupos terapéuticos y principios activos de mayor consumo por el Sistema Nacional de Salud durante 2004. Informe Farmacoterapéutico del Sistema Nacional de Salud. 2005;28:121-124
4. Pincus T, Wang X, Chung C, Sokka T, Koch GG. Patient preference in a crossover clinical trial of patients with osteoarthritis of the knee or hip: face validity of selfreport questionnaire ratings. J Rheumatol. 2005;32:533-539 (Pubitemid 40381428)
5. Rainsford KD. Anti-inflammatory drugs in the 21st century. Subcell Biochem. 2007;42:3-27.
6. Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet. 2007;370:2138-2151
7. Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008;12:1-178. (Pubitemid 351714695)
8. Winzeler S, Rosenstein BD. Non-steroidal antiinflammatory drugs. A review. AAOHN J. 1998;46:253-259
9. Curry SL, Cogar SM, Cook JL. Nonsteroidal antiinflammatory drugs: a review. J Am Anim Hosp Assoc. 2005;41:298-309. (Pubitemid 43180167)
10. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332:1302-1308 (Pubitemid 44365384)
11. Schaffer D, Florin T, Eagle C, Marschner I, Singh G, Grobler M, et al. Risk of serious NSAID-related gastrointestinal events during long-term exposure: a systematic review. Med J Aust. 2006;185:501-506 (Pubitemid 44756212)
12. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115:1634-1642 (Pubitemid 46648649)
13. Szmitko PE, Juurlink D. Review: nonselective nonsteroidal antiinflammatory drugs do not increase risk for cardiovascular events. ACP J Club. 2007;146:12.
14. Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR, Lázaro P, et al. The RAND/ UCLA Appropriateness Method User's Manual. Santa Monica: RAND; 2001.
15. Center for Evidence Based Medicine. Levels of evidence. 2008 [citado 8 Abr 2008]. Disponible en: http://www.cebm.net/index.aspx?o=1025
16. a ed. New York: McGraw Hill; 2001. p. 669.
17. a ed. Madrid: Médica Panamericana; 2001. p. 1-7.
18. Loza E. Revisión sistemática: ¿hay alguna razón para contraindicar el uso concomitante de antiinflamatorios no esteroideos y esteroides? Reumatol Clin. 2008;4:220-227
19. Pocock SJ, McCormack V, Gueyffier F, Boutitie F, Fagard RH, Boissel JP. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. BMJ. 2001;323:75-81. (Pubitemid 32681971)
20. Bennett M. A risk score for cardiovascular disease. 2005 [citado 12 May 2008]. Disponible en: http://www.riskscore.org.uk/
21. Grau M, Marugat J. Funciones de riesgo en la prevención primaria de las enfermedades cardiovasculares. Rev Esp Cardiol. 2008;61:404-416 (Pubitemid 351838469)
22. Horackova M, Charvat J, Hasa J, Forejt J, Kvapil M. Life-threatening renal failure caused by vasomotor nephropathy associated with nonsteroidal anti-inflammatory drugs. Int J Clin Pharmacol Res. 2004;24:117-122 (Pubitemid 40288813)
23. Pincus T, Callahan LF. Variability in individual responses of 532 patients with rheumatoid arthritis to first-line and second-line drugs. Agents Actions Suppl. 1993;44:67-75. (Pubitemid 23211958)
24. Sánchez Gómez LM. Eficacia y seguridad de los antiinflamatorios no esteroideos en pacientes menores de 18 años con dolor de origen músculo-esquelético [citado 1 Ene 2008]. Reumatología basada en la evidencia. Disponible en: http://www.ser.es/ ArchivosDESCARGABLES/consensos/RevAINEsninios.pdf.
25. Loza E. Revisión sistemática: ¿es eficaz y seguro el uso de AINE para los ancianos? Reumatol Clin. 2008;4:172-182
26. Gibofsky A, Williams GW, McKenna F, Fort JG. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. Arthritis Rheum. 2003;48:3102-3111 (Pubitemid 37409321)
27. Cheng TT, Lai HM, Chiu CK, Chem YC. A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis. Clin Ther. 2004;26:399-406. (Pubitemid 38457332)
28. Boulos P, Dougados M, Macleod SM, Hunsche E. Pharmacological treatment of ankylosing spondylitis: a systematic review. Drugs. 2005;65:2111-2127 (Pubitemid 41475792)
29. Bjordal JM, Klovning A, Ljunggren AE, Slordal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomised placebo-controlled trials. Eur J Pain. 2007;11:125-138 (Pubitemid 44829965)
30. Cepeda MS, Camargo F, Zea C, Valencia L. Tramadol for osteoarthritis. Cochrane Database Syst Rev. 2006;(3):CD005522.
31. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006;(2):CD005328.
32. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006;(2):CD005321.
33. Loza E. Revisión sistemática sobre la seguridad del uso concomitante de fármacos hipoglucemiantes y antiinflamatorios no esteroideos en pacientes con enfermedad reumática. Reumatol clin. 2008;4:232-239
34. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113:2363-2372
35. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520-1528 (Pubitemid 30844348)
36. Loza E. Revisión sistemática sobre la seguridad del uso concomitante de fármacos hipoglucemiantes y antiinflamatorios no esteroideos en pacientes con enfermedad reumática. Reumatol clin. 2008;4:232-239
37. Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ. 2007;177:347-351 (Pubitemid 47339530)
38. Knijff-Dutmer EA, Schut GA, van de Laar MA. Concomitant coumarin-NSAID therapy and risk for bleeding. Ann Pharmacother. 2003;37:12-16 (Pubitemid 36068591)
39. Knijff-Dutmer EA, Van der Palen J, Schut G, Van de Laar MA. The influence of cyclooxygenase specificity of non-steroidal anti-inflammatory drugs on bleeding complications in concomitant coumarine users. QJM. 2003;96:513-520 (Pubitemid 36850167)
40. Hilleman DE, Mohiuddin SM, Lucas BD Jr. Nonsteroidal antiinflammatory drug use in patients receiving warfarin: emphasis on nabumetone. Am J Med. 1993;95:S30-4.
41. Nishishinya B, Loza E. Revisión sistemática: ¿qué AINE presenta un menor riesgo de toxicidad renal? [citado 1 Ene 2008]. Reumatología basada en la evidencia. Disponible en: http://www.ser.es/ArchivosDESCARGABLES/consensos/RevAINEstoxrenal.pdf.
42. Hidalgo Natera A, Cardenas Contreras R, Najem Risk N, Canto Diez G. meningitis aséptica probablemente inducida por ibuprofeno en una paciente con lupus eritematoso sistémico. Med Clin (Barc). 2004;122:678-679 (Pubitemid 38747212)
43. Martínez López JA. Revisión sistemática: ¿es seguro el uso de AINE durante el embarazo? Reumatol Clin. 2008;4:191-196